title: Novel Targeted Therapies for Inflammatory Bowel Disease.
abstract: Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.
authors.affiliation: Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Denmark; The Bioinformatics Centre, Department of Biology, and Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Coskun
authors.affiliation: Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
authors.forename: Severine
authors.initials: S
authors.lastname: Vermeire
authors.affiliation: Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Denmark. Electronic address: ohn@dadlnet.dk.
authors.forename: Ole Haagen
authors.initials: OH
authors.lastname: Nielsen
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010069:Oxadiazoles / Q000627:therapeutic use; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D057285:Precision Medicine; D052999:Quinazolinones / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D051906:Smad7 Protein / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007189:Indans; D053759:Interleukin-23; D053613:Janus Kinase 1; D016376:Oligonucleotides, Antisense; D010069:Oxadiazoles; D010649:Phenylalanine; D052999:Quinazolinones; D015363:Quinolones; D051906:Smad7 Protein; D000093242:Interleukin-6 Inhibitors; C000588820:AJM300; C476223:laquinimod; C543529:vedolizumab; C000607776:ozanimod
keywords: Crohn's disease; antisense therapy; biologics; leukocyte trafficking; small molecules; ulcerative colitis